Document Detail

Efficacy of gemifloxacin for the treatment of experimental Staphylococcus aureus keratitis.
MedLine Citation:
PMID:  22360669     Owner:  NLM     Status:  MEDLINE    
PURPOSE: The objective of the present study was to evaluate the effectiveness of topically applied gemifloxacin for the treatment of experimental Staphylococcus aureus keratitis in a rabbit model.
METHODS: Rabbit corneas were intrastromally injected with ~100 colony-forming units (CFU) of S. aureus ATCC25923. Eight hours (early treatment) or 16 h (late treatment) after the injection, 1 topical drop of balanced salt solution (BSS), gemifloxacin ophthalmic solution (0.5%), levofloxacin ophthalmic solution (0.5%), or gatifloxacin eye gel (0.3%) was applied to each eye every 15 min for 5 doses and then, every 30 min for 14 doses. The eyes were examined both before and after treatment. The corneas were harvested from treated and untreated rabbits for the quantitation of bacteria and histological observation.
RESULTS: In the early-treatment groups, all 3 fluoroquinolones significantly lowered the clinical severity of infection and the median erosion area of the cornea compared with the BSS control (P=0.000). In the late-treatment groups, gemifloxacin and levofloxacin did not cause a significant reduction in clinical scores compared with the BSS control (P=0.107 and 0.531, respectively), but the gatifloxacin caused a significant reduction in clinical scores compared with the BSS control (P=0.011). The median erosion area significantly decreased with treatment with gemifloxacin, gatifloxacin, and levofloxacin in both early- and late-treatment groups, when compared with the control group (P≤0.022). In the early-treatment groups, the gemifloxacin, gatifloxacin, and levofloxacin groups had significantly lower CFU recovered from the corneas compared with the control group (P<0.01), while in the late-treatment groups, levofloxacin failed to reduce the CFU recovered from the corneas compared with the control group (P=0.695). The minimal inhibitory concentrations for gemifloxacin, gatifloxacin, and levofloxacin against S. aureus ATCC25923 were 0.0625, 0.0625, and 0.125 mg/L, respectively.
CONCLUSIONS: Gemifloxacin, similar to gatifloxacin and levofloxacin, can significantly lower the clinical severity and CFU per cornea observed in S. aureus keratitis when early treatment is implemented. Significantly, gemifloxacin showed a significant efficacy improvement in reducing the bacterial load recovered from the corneas in the late-treatment experiment.
Xianggen Wu; Haoran Jiang; Yuanyuan Xu; Wenjie Yue; Lingling Yang; Zicheng Song; Hao Chen; Ting Liu
Related Documents :
16238909 - Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhib...
20150839 - The influence of simvastatin on selected inflammatory markers in patients with chronic ...
9523539 - Ldl apheresis for arteriosclerosis obliterans with occluded bypass graft: change in pro...
15378139 - Effects of low-dose atorvastatin on vascular responses in patients undergoing percutane...
12671829 - Effect of oral calcitriol pulse therapy on the lipid, calcium, and glucose homeostasis ...
14624049 - Long-term hemostatic effects of cholesterol-lowering therapy with atorvastatin.
14741819 - Response of spider leg veins to pulsed diode laser (810 nm): a clinical, histological a...
10775939 - Biliopancreatic diversion with gastrectomy as surgical treatment of morbid obesity.
25357079 - Objective optical quality analysis using double-pass technique in pterygium surgery.
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't     Date:  2012-02-23
Journal Detail:
Title:  Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics     Volume:  28     ISSN:  1557-7732     ISO Abbreviation:  J Ocul Pharmacol Ther     Publication Date:  2012 Aug 
Date Detail:
Created Date:  2012-07-31     Completed Date:  2012-12-04     Revised Date:  2013-04-24    
Medline Journal Info:
Nlm Unique ID:  9511091     Medline TA:  J Ocul Pharmacol Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  420-7     Citation Subset:  IM    
State Key Laboratory Cultivation Base, Shandong Provincial Key Laboratory of Ophthalmology, Shandong Eye Institute, Shandong Academy of Medical Sciences, No. 5 Yanerdao Rd., Qingdao, P.R. China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anti-Infective Agents, Local / administration & dosage,  pharmacology,  therapeutic use*
Colony Count, Microbial
Conjunctival Diseases / drug therapy,  microbiology
Cornea / microbiology,  pathology
Eye / microbiology
Fluoroquinolones / administration & dosage,  pharmacology,  therapeutic use*
Keratitis / drug therapy*,  microbiology
Microbial Sensitivity Tests
Naphthyridines / administration & dosage,  pharmacology,  therapeutic use*
Ofloxacin / administration & dosage,  pharmacology,  therapeutic use
Staphylococcal Infections / drug therapy*,  microbiology
Staphylococcus aureus / drug effects*
Reg. No./Substance:
0/Anti-Infective Agents, Local; 0/Fluoroquinolones; 0/Naphthyridines; 82419-36-1/Ofloxacin; L4618BD7KJ/gatifloxacin; OKR68Y0E4T/gemifloxacin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Two Possibilities How to Increase the Efficacy of Antidotal Treatment of Nerve agent Poisonings.
Next Document:  Pivotal role of anthranilate dioxygenase genes in the adaptation of Burkholderia multivorans ATCC 17...